US · Healthcare · Drug Manufacturers - General
EPS came in at 2.04 against a street estimate of 1.59 — a beat of 28.3%.
Analysts rate Bristol-Myers Squibb Company a hold (10 buy, 18 hold, 1 sell out of 29) with an average price target of $66.42.
CONFIDENT BMS beat Q2 estimates with 5% revenue growth and strong growth portfolio (+14%). Raised FY26 guidance on Eliquis strength. Multiple pipeline readouts expected by year-end including Admilparant (IPF), Iberdomide (CELMoD), and Sotyktu (lupus). Q2 2026 Call did not segment by geography; U.S. and international referenced within product discussions. Analysts pressed on Milvexian efficacy expectations, IPF market dynamics, Cobenfy titration delays, and CELMoD revenue contribution. Management emphasized noninferiority design, unmet tolerability needs, and confidence in science quality over speed. 2026-07-30…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 8.40% |
| Vanguard Capital Management, LLC | 6.48% |
| State Street Corp | 4.83% |
| JPMorgan Chase & Co | 4.53% |
| Charles Schwab Investment Management Inc | 2.99% |
| Geode Capital Management, LLC | 2.71% |
| Vanguard Portfolio Management, LLC | 2.26% |
| NORGES BANK | 1.80% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 BRISTOL-MYERS SQUIBB COMPANY – FORM 10-Q SUMMARY Period Ended June 30, 2026 --- HEADLINE NUMBERS • Net product sales Q2 2026: $12,588 million vs. $ | 2026-07-30 |
| Results announced · Q3 2026 BRISTOL-MYERS SQUIBB Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q2 2026 Total Revenues: $13.0 billion, up 6% (+5% excluding foreign exchange) versu | 2026-07-30 |
| Shareholder vote results · Q2 2026 BRISTOL-MYERS SQUIBB COMPANY – FORM 8-K SUMMARY HEADLINE NUMBERS • Annual shareholder meeting held May 5, 2026 • Total votes cast across proposals: | 2026-05-08 |
| Quarterly report · Q1 2026 BRISTOL-MYERS SQUIBB COMPANY — Q1 2026 FORM 10-Q SUMMARY HEADLINE NUMBERS • Total Revenues: $11,489 million (Q1 2026) vs. $11,201 million (Q1 2025) | 2026-04-30 |
| Results announced · Q2 2026 BRISTOL-MYERS SQUIBB Q1 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Total Q1 2026 revenues: $11.5 billion, up 3% reported (+1% excluding forei | 2026-04-30 |
| Proxy statement · Q2 2026 BRISTOL-MYERS SQUIBB PROXY STATEMENT (DEF 14A) SUMMARY FOR RETAIL INVESTORS --- CEO COMPENSATION & CHANGE • Christopher S. Boerner (CEO) total comp | 2026-03-25 |
| Annual report FY2025 BRISTOL-MYERS SQUIBB COMPANY – FORM 10-K SUMMARY Fiscal Year Ended December 31, 2025 --- HEADLINE NUMBERS • Total Revenues 2025: $48,194 million (e | 2026-02-11 |
| Results announced · Q1 2026 BRISTOL MYERS SQUIBB - 2025 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Q4 2025 Total Revenues: $12.5 billion, up 1% vs. Q4 2024 • Q4 2025 Non-GAAP | 2026-02-05 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | $0.63 / share ex-date Oct 2, 2026 · pay Nov 2, 2026 | 2026-10-02 |
| Dividend | $0.63 / share ex-date Jul 2, 2026 · pay Aug 3, 2026 | 2026-07-02 |
| Dividend | $0.63 / share ex-date Apr 2, 2026 · pay May 1, 2026 | 2026-04-02 |
| Dividend | $0.63 / share ex-date Jan 2, 2026 · pay Feb 2, 2026 | 2026-01-02 |
| Dividend | $0.62 / share ex-date Oct 3, 2025 · pay Nov 3, 2025 | 2025-10-03 |
| Announcement | Date |
|---|---|
| Q1 2026 results reported; 2026 guidance reaffirmed, trending toward upper end Bristol Myers Squibb reported Q1 2026 results showing solid execution with revenues of $11.5 billion, up 3% year-over-year (1% excluding currency effects). The company's Growth Portfolio—new | 2026-04-30 |
| 2026 revenue and EPS guidance provided; dividend increased Bristol Myers Squibb reported 2025 results showing disciplined execution with mixed but encouraging trends. Total revenues were $48.2 billion (flat year-over-year), but the Growth Portfolio— | 2026-02-05 |
| Raising 2025 revenue guidance to $47.5-48.0 billion range Bristol Myers Squibb reported Q3 2025 results showing solid momentum despite mixed signals. Total revenues grew 3% ($12.2 billion) with growth accelerating when excluding foreign exchange he | 2025-10-30 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Bristol-Myers Squibb Company — free to start.
Google PlayApp StoreData updated 2026-09-18.